Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation

Kidney International

Volumn 56, Issue 2, 1999, Pages 738-746

  Schnuelle, Peter ^a,b   Lorenz, Dietmar ^a,b   Mueller, Alexander ^a,b   Trede, Michael ^a,b   Van Der Woude, Fokko Johannes ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Acute rejection; Brain death; Catecholamines; Graft survival; Kidney transplantation

Indexed keywords

CATECHOLAMINE; CELL ADHESION MOLECULE; CYCLOSPORIN; DOBUTAMINE; DOPAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HLA DR ANTIGEN; HYPERTENSIVE FACTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; OKT 3; THYMOCYTE ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE; ARTICLE; BRAIN DEATH; BRAIN INJURY; CADAVER KIDNEY; CONTROLLED STUDY; DRUG USE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL;

EID: 0032776671     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00567.x     Document Type: Article

References (42)

1. 1. AGODA LY, EGGERS PW: Renal replacement therapy in the United States: Data from the United States Renal Data System. Am J Kidney Dis 25:119-133, 1995
2. 2. MALLICK NP, JONES E, SELWOOD N: The European (European Dialysis and Transplantation Association-European Renal Association) Registry. Am J Kidney Dis 25:176-187, 1995
3. 3. OPELZ G: Collaborative transplant study: 10 year report. Transplant Proc 24:2342-2355, 1992
4. 4. CECKA JM: Outcome statistics of renal transplants with emphasis on long-term survival. Clin Transplant 8:324-327, 1994
5. 5. TAKEMOTO S, TERASAKI PI, CECKA JM, CHO YW, GJERTSON DW: Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors: The UNOS Scientific Renal Transplant Registry, N Engl J Med 327:834-839, 1992
6. 6. TERASAKI PI, GJERTSON DW, CECKA JM, TAKEMOTO S, CHO YW: Significance of the donor age effect on kidney transplants. Clin Transplant 11:366-372, 1997
7. 7. FERGUSON R: Acute rejection episodes: Best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 8:328-331, 1994
8. 8. CECKA JM, CHO YW, TERASAKI PI: Analysis of the UNOS Scientific Renal Transplant Registry at three years: Early events affecting transplant success. Transplantation 53:59-64, 1992
9. 9. VAN SAASE JLCM, VAN DER WOUDE FJ, THOROGOOD J: The relationship between acute vascular and interstitial allograft rejection and subsequent chronic rejection. Transplantation 59:1280-1285, 1995
10. 10. HALLORAN PF, APRILE MA, FAREWELL V, LUDWIN D, SMITH EK, TSAI SY, BEAR RA, COLE EH, FENTON SS, CAITRAN DC: Early function as the principal correlate of graft survival. Transplantation 46:223-228, 1988
11. 11. TERASAKI PI, CECKA JM, GJERTSON DW, TAKEMOTO S: High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 333:333-336, 1995
12. 12. PIENAAR H, SCHWARTZ I, RONCONE A, LOTZ Z, HICKMAN R: Function of kidney grafts from brain-dead donor pigs: The influence of dopamine and triiodothyronine. Transplantation 50:580-582, 1990
13. 13. WALASZEWSKI J, ROWINSKI W, CHMURA A, CAJZNER S, KOWALCZYK J, DANIELEWICZ R, MICHALAK G, NAWROCKI G, LAZOWSKI T, ZAWADZKI A, LAO M, ORLOWSKI T: Decreased incidence of acute tubular necrosis after cadaveric donor transplantation due to lidocaine donor pretreatment and low-dose dopamine infusion in the recipient. Transplant Proc 20:913, 1988
14. 14. CARMELLINI M, ROMAGNOLI J, GIULIANOTTI PC, PIETRABISSA A, DI STEFANO R, RINDI O, RIZZO G, MOSCA F: Dopamine lowers the incidence of delayed graft function in transplanted kidney patients treated with cyclosporine A. Transplant Proc 26:2626-2629, 1994
15. 15. GRUNDMANN R, KINDLER J, MEIDER G, STOWE H, SIEBERTH HG, PICHLMAIER H: Dopamine treatment of human cadaver kidney graft recipients: A prospectively randomised trial. Klin Wochenschr 60:193-197, 1982
16. 16. SANDBERG J, TYDEN G, GROTH CG: Low-dose dopamine infusion following cadaveric renal transplantation: No effect on the incidence of ATN. Transplant Proc 24:357, 1992
17. 17. KADIEVA VS, FRIEDMAN L, MARGOLIUS LP, JACKSON SA, MORRELL DF: The effect of dopamine on graft function in patients undergoing renal transplantation. Anesth Analg 76:362-365, 1993
18. 18. FERGUSON CJ, HILLIS AN, WILLIAMS JD, GRIFFIN PJ, SALAMAN JR: Calcium-channel blockers and other factors influencing delayed function in renal allografts. Nephrol Dial Transplant 5:816-820, 1990
19. 19. O'BRIEN EA, BOUR SA, MARSHALL RL, AHSAN N, YANG HC: Effect of use of vasopressors in organ donors on immediate function of renal allografts. J Transplant Coord 6:215-216, 1996
20. 20. MARSHALL R, AHSAN N, DHILLON S, HOLMAN M, YANG HC: Adverse effect of donor vasopressor support on immediate and one-year kidney allograft function. Surgery 120:663-665, 1996
21. 21. SUTHERLAND FR, BLOEMBERGEN W, MOHAMED M, OSTBYE T, KLAR N, LAZAROVITS AI: Initial non function in cadaveric renal transplantation. Can J Surg 36:141-145, 1993
22. 22. YAMAOKA Y, TAKI Y, GUBERNATIS G, NAKATANI T, OKAMOTO R, YAMAMOTO Y, ISHIKAWA Y, RINGE B, BUNZENDAHL H, OELLERICH M: Evaluation of the liver graft before procurement: Significance of arterial ketone body ratio in brain-dead patients. Transplant Int 3:78-81, 1990
23. 23. NAKATANI T, ISHIKAWA Y, KOBAYASHI K, OZAWA K: Hepatic mitochondrial redox state in hypotensive brain-dead patients and an effect of dopamine administration. Intensive Care Med 17:103-107, 1991
24. 24. MANAKA D, OKAMOTO R, YOKOYAMA T, YAMAMOTO Y, WASHIDA M, INO K, YAMAOKA Y, KUMADA K, OZAWA K: Maintenance of liver graft viability in the state of brain death: Synergistic effects of vasopressin and epinephrine on hepatic energy metabolism in brain-dead dogs. Transplantation 53:545-550, 1992
25. 25. ARVIN B, NEVILLE LF, BARONE FC, FEUERSTEIN GZ: The role of cytokines in brain injury. Neurosci Biobehav Rev 20:445-452, 1996
26. 26. FEUERSTEIN GZ, LIU T, BARONE FC: Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 6:341-360, 1994
27. 27. BETZ AL, SCHIELKE GP, YANG GY: Interleukin-1 in cerebral ischemia. Keio J Med 45:230-237, 1996
28. 28. KIM JS: Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 137:69-78, 1996
29. 29. DUSTIN ML, ROTHLEIN R, BHAN AF, DINARELLO CA, SPRINGER TA: A natural adherence molecule (ICAM-1): Induction by IL-1 and IFN-γ, tissue distribution, biochemistry, and function. J Immunol 137:245-254, 1986
30. 30. POBER JS, BEVILACQUA MP, MENDRICK DL, LAPIERE LA, FIERS W, GIMBRONE MA JR: Two distinct monokines, interleukin-1 and tumor necrosis factor, independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136:1680-1687, 1986
31. 31. CARLOS TM, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood 84:2068-2101, 1994
32. 32. CARLOS TM, CLARKS RS, FRANICOLA-HIGGINS D, SCHIDING JK, KOCHANEK PM: Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats. J Leukoc Biol 61:279-285, 1997
33. 33. STANIMIROVIC DB, WONG J, SHAPIRO A, DUKKIN JP: Increase in surface expression of ICAM-1, VCAM-1 and E-selectin in human cerebromicrovascular endothelial cells subjected to ischemia-like insults. Acta Neurochir (Wien) 70(Suppl):12-16, 1997
34. 34. POBER JS, SLOWIK MR, DE LUCA LG, RITCHIE AJ: Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J Immunol 150:5114-5123, 1993
35. 35. FORTENBERRY JD, HUBER AR, OWENS ML: Inotropes inhibit endothelial cell surface adhesion molecules induced by interleukin-1β. Crit Care Med 25:303-308, 1997
36. 36. SHOSKES DA, CECKA JM: Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 66:1697-1701, 1998
37. 37. OJO AO, WOLFE RA, HELD PJ, PORT FK, SCHMOUDER RL: Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 63:968-974, 1997
38. 38. LEHTONEN SR, ISONIEMI HM, SALMELA KT, TASKINEN EI, VON WILLEBRAND EO, AHONEN JP: Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection. Transplantation 64:103-107, 1997
39. 39. MARCEN R, OROFINO L, PASCUAL J, DE LA CAL MA, TERUEL JL, VILLAFRUELA JJ, RIVERA ME, MAMPASO F, BURGOS FJ, ORTUNO J: Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation 66:461-466, 1998
40. 40. HAUG CE, COLVIN RB, DELMONICO FL, AUCHINCLOSS H JR, TOLKOFF-RUBIN N, PREFFER FI, ROTHLEIN R, NORRIS S, SCHARSCHMIDT L, COSIMI AB: A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 55:766-772, 1993
41. 41. HOURMANT M, BEDROSSIAN J, DURAND D, LEBRANCHU Y, RENOULT E, CAUDRELIER P, BUFFET R, SOULILLOU JP: A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 62:1565-1570, 1996
42. 42. MASSY ZA, GUIJARRO C, KASISKE BL: Clinical predictors of chronic renal allograft rejection. Kidney Int 52(Suppl):S85-S88, 1995